Lung adenocarcinoma — what your diagnosis means

Lung adenocarcinoma is the most common type of lung cancer. It is a form of non-small cell lung cancer (NSCLC) that begins in the gland cells lining the airways. It usually develops in the outer (peripheral) parts of the lung. Adenocarcinoma is also the lung cancer most often diagnosed in people who have never smoked, particularly women. Importantly, it is not a single disease — many adenocarcinomas are driven by a specific gene change such as EGFR, ALK, or ROS1, which is why the biopsy must be tested fully before treatment is chosen.

Adenocarcinoma is a serious diagnosis, but how it behaves varies a great deal from person to person. The outlook depends mainly on the stage at diagnosis and on the molecular result. Earlier-stage cancers that can be removed with surgery have a very different outlook from advanced cancers. For cancers with a targetable driver such as EGFR or ALK, modern tablets can control the disease for long periods. The most reliable guide to your own situation is your oncologist's assessment after reviewing your full report — not a general statistic.

There is no single number for adenocarcinoma prognosis. It depends on the stage at diagnosis, the molecular result, your general health, and how the cancer responds to treatment. Survival figures online are averages from large groups and cannot predict any one person's outcome. The encouraging part is that adenocarcinoma care has changed dramatically in the last decade — targeted tablets for EGFR, ALK, and ROS1 cancers can control the disease for long periods with fewer side effects than chemotherapy. Testing the biopsy fully and choosing treatment from the result is what most improves the outlook.

Yes — adenocarcinoma is the lung cancer most often seen in people who have never smoked, especially women. In these patients it is frequently driven by a gene change such as an EGFR mutation rather than tobacco damage. In India, a large share of non-smoker adenocarcinomas carry an EGFR mutation. A lung cancer diagnosis in a non-smoker is not unusual in India and is not a mistake. It does, however, make molecular testing of the biopsy especially important, because EGFR-mutated cancer responds dramatically to a daily targeted tablet.

Because adenocarcinoma is so often driven by a targetable mutation, the biopsy report alone is not enough to plan treatment. Testing for EGFR, ALK, ROS1, and PD-L1 determines the most effective option. An EGFR-mutated cancer is best treated with a daily oral tablet, not chemotherapy or immunotherapy — and starting the wrong treatment first can deny a patient the more effective, better-tolerated option. At CION, molecular testing is reviewed as a standard step before any treatment is finalised for advanced adenocarcinoma.

Early adenocarcinoma often causes no symptoms and may be found by chance on a scan. When symptoms appear they are easy to overlook: a persistent cough lasting more than 3 weeks or a change in a long-standing cough, unexplained breathlessness, coughing up blood, persistent chest or shoulder pain, recurring chest infections in the same part of the lung, and unexplained weight loss or fatigue. Because the tumour usually sits in the outer lung, it can grow for some time before causing symptoms — which is why any symptom that does not settle in 3 weeks should be evaluated.

Diagnosis usually starts with a chest X-ray and CT scan to find the abnormality, followed by a biopsy to confirm it is adenocarcinoma under the microscope. The same biopsy tissue is then tested for gene changes (EGFR, ALK, ROS1) and PD-L1, which is essential for planning treatment. A PET-CT scan is used to stage the cancer and check for spread. The biopsy method — CT-guided needle, bronchoscopy, or EBUS — depends on where the abnormality sits in the lung.

Treatment is chosen from the stage and the molecular result together. Early-stage cancers are often treated with surgery, sometimes with radiation. For cancers with a driver mutation such as EGFR, ALK, or ROS1, a matched daily tablet (targeted therapy) is usually more effective and better tolerated than chemotherapy. When no driver mutation is found, immunotherapy — alone or with chemotherapy — is guided by the PD-L1 level. Most patients receive a combined plan agreed by a tumour board, alongside nutrition and supportive care.

Adenocarcinoma is one subtype of non-small cell lung cancer (NSCLC); the other main NSCLC subtype is squamous cell carcinoma. Small cell lung cancer is a separate, faster-growing type that is treated differently. Adenocarcinoma tends to arise in the outer lung, is the most common type overall, is the type most often seen in non-smokers, and is the most likely to carry a targetable driver mutation. That last point is the key practical difference, because it means molecular testing can open up treatment options that other subtypes may not have.

Yes, and it is particularly worthwhile in adenocarcinoma. A second opinion is most valuable if treatment has been recommended without molecular testing of the biopsy, or if immunotherapy has been suggested before confirming whether the cancer carries an EGFR mutation. CION offers a dedicated second opinion service, including a free written opinion, so you can make a confident, informed decision before treatment begins.

Yes. CION Cancer Clinics evaluates and treats lung adenocarcinoma across Hyderabad with a multidisciplinary team of medical, surgical, and radiation oncologists. Every case is reviewed by a tumour board, molecular testing is arranged from the biopsy as standard, and consultations run 45 minutes so decisions are never rushed. CION operates 35+ centres across Telangana and Andhra Pradesh and is rated 4.8/5 by over 1,000 patients on Google.